Ignite Creation Date:
2024-05-06 @ 1:07 PM
Last Modification Date:
2024-10-26 @ 1:09 PM
Study NCT ID:
NCT03936192
Status:
WITHDRAWN
Last Update Posted:
2022-04-18
First Post:
2019-04-29
Brief Title:
A Parallel-group Active Comparator Double-blind Multicenter Randomized Double-blind Phase III Clinical Study
Sponsor:
Eurofarma Laboratorios SA
Organization:
Eurofarma Laboratorios SA
Study Overview
Official Title:
Parallel-group Active Comparator Double-blind Randomized Phase III Study to Assess Safety Efficacy of Glucosamine Sulfate Plus Meloxicam vs Glucosamine Sulfate Plus Chondroitin Sulfate Primary Symptomatic Knee Osteoarthritis Treatment
Status:
WITHDRAWN
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Company decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SAVE
Brief Summary:
A multicenter randomized double-blind parallel-group placebo-controlled and active-drug 12-week multicenter clinical study Participants will be randomized 2 2 1 to receive the combination of glucosamine sulfate meloxicam experimental group combination of glucosamine sulfate chondroitin sulfate active control group or placebo
Detailed Description:
A multicenter randomized double-blind parallel-group placebo-controlled and active-drug 12-week treatment period phase 3 comparative clinical study Participants will be randomized 221 to receive the combination of glucosamine sulfate meloxicam experimental group combination of glucosamine sulfate chondroitin sulfate active control group or placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None